These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 17220245

  • 21. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L, Yang X, Yang Z, Gao S, Yin T, Liu W, Wang F, Hu M, Liu Z.
    Toxicol Lett; 2013 Feb 04; 216(2-3):86-99. PubMed ID: 23200901
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R, Jadhav G, Vangala S.
    Curr Pharm Biotechnol; 2017 Feb 04; 18(14):1151-1158. PubMed ID: 29521222
    [Abstract] [Full Text] [Related]

  • 23. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
    Gong IY, Mansell SE, Kim RB.
    Basic Clin Pharmacol Toxicol; 2013 Mar 04; 112(3):164-70. PubMed ID: 22958812
    [Abstract] [Full Text] [Related]

  • 24. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
    Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M.
    Drug Metab Dispos; 2004 Jan 04; 32(1):20-7. PubMed ID: 14709616
    [Abstract] [Full Text] [Related]

  • 25. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
    Yang C, Zhang T, Li Z, Xu L, Liu F, Ruan J, Liu K, Zhang Z.
    Toxicol Appl Pharmacol; 2013 Dec 15; 273(3):561-8. PubMed ID: 24120885
    [Abstract] [Full Text] [Related]

  • 26. Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.
    Li YH, Bi HC, Huang L, Jin J, Zhong GP, Zhou XN, Huang M.
    Acta Pharmacol Sin; 2014 Feb 15; 35(2):283-91. PubMed ID: 24362330
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical safety of licorice flavonoid oil (LFO) and pharmacokinetics of glabridin in healthy humans.
    Aoki F, Nakagawa K, Kitano M, Ikematsu H, Nakamura K, Yokota S, Tominaga Y, Arai N, Mae T.
    J Am Coll Nutr; 2007 Jun 15; 26(3):209-18. PubMed ID: 17634165
    [Abstract] [Full Text] [Related]

  • 30. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV, Wang J, Lee FY, Marathe PH.
    Cancer Chemother Pharmacol; 2008 Mar 15; 61(3):365-76. PubMed ID: 17429625
    [Abstract] [Full Text] [Related]

  • 31. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
    Xiao G, Black C, Hetu G, Sands E, Wang J, Caputo R, Rohde E, Gan LS.
    Drug Metab Dispos; 2012 Apr 15; 40(4):779-87. PubMed ID: 22266779
    [Abstract] [Full Text] [Related]

  • 32. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y.
    Drug Metab Dispos; 2007 Jul 15; 35(7):1142-8. PubMed ID: 17446265
    [Abstract] [Full Text] [Related]

  • 33. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O.
    Cancer Res; 2002 Nov 01; 62(21):6158-64. PubMed ID: 12414642
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.
    Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, Fenner KS, Troutman MD.
    J Pharm Sci; 2009 Dec 01; 98(12):4914-27. PubMed ID: 19373887
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG.
    Drug Metab Dispos; 2013 Apr 01; 41(4):827-35. PubMed ID: 23382458
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.